Table II.
Selected ongoing trials of anlotinib in cancer treatment.
| Clinical trial identifier | Phase | Indication | Setting | Intervention | Primary endpoint | Status |
|---|---|---|---|---|---|---|
| NCT03589950 | II | Advanced non-small-cell lung cancer | Second line | Anlotinib plus chemotherapy | PFS survival and DCR | Not yet recruiting |
| NCT03755869 | IV | Non-squamous non-small-cell lung cancer | Second line | Anlotinib | PFS | Not yet recruiting |
| NCT03618238 | II | Stage IV extranodal natural killer/T-cell lymphoma, nasal type | Second line | Anlotinib | Overall response rate | Recruiting |
| NCT02072044 | II | Advanced renal cell carcinoma | Second line | Anlotinib | PFS | Active, not recruiting |
| NCT03387904 | II | Esophageal squamous cell carcinoma | Second line | Anlotinib plus irinotecan | PFS and DCR | Not yet recruiting |
| NCT03924882 | II | Ovarian cancer | Second or further line | Anlotinib | Objective response rate | Recruiting |
| NCT03416517 | I/II | Ewing's tumor metastatic | Second line | Anlotinib and irinotecan | MTD (phase Ib), Object response rate (phase II) | Recruiting |
| NCT03591666 | II | Head and neck carcinoma, adenocarcinoma, recurrent disease, distantly metastatic malignant neoplasm | Second line | Anlotinib | Objective response rate | Not yet recruiting |
| NCT03016819 | III | Alveolar soft part sarcoma, leiomyosarcoma and synovial sarcoma | Second line | Anlotinib | Objective response rate and PFS | Recruiting |
| NCT03792542 | II | Advanced soft-tissue sarcoma | First or second line | Anlotinib | PFS | Not yet recruiting |
| NCT03946943 | II | Soft-tissue sarcomas, undifferentiated pleomorphic sarcoma | First line | Anlotinib plus toripalimab | Rate of participants achieving 3-month PFS | Not yet recruiting |
| NCT03545711 | I/II | Colorectal cancer | Second line | Anlotinib plus irinotecan | MTD, overall response rate | Recruiting |
| NCT03457844 | II | Gastroenteropancreatic neuroendocrine tumor G3 | Second line | Anlotinib | PFS | Recruiting |
| NCT02461407 | II/III | Gastric cancer | Third or further line | Anlotinib | OS | Recruiting |
| NCT03855358 | Ib | Triple-negative breast cancer | Second line | Anlotinib plus PD-L1 inhibitorin | Overall response rate | Not yet recruiting |
PFS, progression-free survival; OS, overall survival; DCR, disease control rate; MTD, maximum tolerated dose; PD-L1, programmed cell death 1 ligand 1.